Targeting the nasty nestin to shoot lung fibrosis. Issue 5 (5th May 2022)

• Record Type: Journal Article
• Authors: Burgy, Olivier; Crestani, Bruno; Bonniaud, Philippe
• Is Part Of: European respiratory journal. Volume 59:Issue 5(2022)
• Publication Date: 2022-05-05
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.03146-2021
• Languages: English
• ISSNs: 0903-1936

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and fatal lung disease [1]. Therapeutic options are limited to pirfenidone and nintedanib, which can slow down but not halt or reverse disease progression. The biology of IPF is highly complex and not fully elucidated, although many actors and mechanisms have been identified in the past decades [2]. Notably, the reactivation of developmental signalling pathways such as transforming growth factor (TGF)-β or WNT signalling has been repeatedly observed during IPF [3–5]. The seminal role of TGF-β in organ fibrogenesis, and more particularly in pulmonary fibrosis, has been known for more than a quarter of century [6]. Nevertheless, the reasons why these observations have not yet turned into effective therapy in IPF raise questions. Nestin promotes TGF-β signalling and is a therapeutic target in IPF https://bit.ly/3Km1rEy